Individualizing duration of antibiotic therapy in community-acquired pneumonia

Stefano Aliberti, Julio Ramirez, Fabio Giuliani, Timothy Wiemken, Giovanni Sotgiu, Sara Tedeschi, Manuela Carugati, Vincenzo Valenti, Marco Marchioni, Marco Camera, Roberto Piro, Manuela Del Forno, Giuseppe Milani, Paola Faverio, Luca Richeldi, Martina Deotto, Massimiliano Villani, Antonio Voza, Eleonora Tobaldini, Mauro BernardiAndrea Bellone, Matteo Bassetti, Francesco Blasi

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

International experts suggest tailoring antibiotic duration in community-acquired pneumonia (CAP) according to patients' characteristics. We aimed to assess the effectiveness of an individualized approach to antibiotic duration based on time in which CAP patients reach clinical stability during hospitalization. In a multicenter, non-inferiority, randomized, controlled trial hospitalized adult patients with CAP reaching clinical stability within 5 days after hospitalization were randomized to a standard vs. individualized antibiotic duration. In the Individualized group, antibiotics were discontinued 48 h after the patient reached clinical stability, with at least five days of total antibiotic treatment. Early failure within 30 days was the primary composite outcome. 135 patients were randomized to the Standard group and 125 to the Individualized group. The trial was interrupted by the safety committee because of an apparent inferiority of the Individualized group over the Standard treatment: 14 (11.2%) patients in the Individualized group experienced early failure vs. 10 (7.4%) patients in the Standard group, p = 0.200, at the intention-to-treat analysis. 30-day mortality rate was four-time higher in the Individualized group than the Standard group. Shortening antibiotic duration according to patients' characteristics still remains an open question.

Original languageEnglish
Pages (from-to)191-201
Number of pages11
JournalPulmonary Pharmacology and Therapeutics
Volume45
DOIs
Publication statusPublished - Aug 1 2017

Fingerprint

Pneumonia
Anti-Bacterial Agents
Therapeutics
Hospitalization
Intention to Treat Analysis
Composite materials
Safety
Mortality

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Biochemistry, medical
  • Pharmacology (medical)

Cite this

Individualizing duration of antibiotic therapy in community-acquired pneumonia. / Aliberti, Stefano; Ramirez, Julio; Giuliani, Fabio; Wiemken, Timothy; Sotgiu, Giovanni; Tedeschi, Sara; Carugati, Manuela; Valenti, Vincenzo; Marchioni, Marco; Camera, Marco; Piro, Roberto; Del Forno, Manuela; Milani, Giuseppe; Faverio, Paola; Richeldi, Luca; Deotto, Martina; Villani, Massimiliano; Voza, Antonio; Tobaldini, Eleonora; Bernardi, Mauro; Bellone, Andrea; Bassetti, Matteo; Blasi, Francesco.

In: Pulmonary Pharmacology and Therapeutics, Vol. 45, 01.08.2017, p. 191-201.

Research output: Contribution to journalArticle

Aliberti, S, Ramirez, J, Giuliani, F, Wiemken, T, Sotgiu, G, Tedeschi, S, Carugati, M, Valenti, V, Marchioni, M, Camera, M, Piro, R, Del Forno, M, Milani, G, Faverio, P, Richeldi, L, Deotto, M, Villani, M, Voza, A, Tobaldini, E, Bernardi, M, Bellone, A, Bassetti, M & Blasi, F 2017, 'Individualizing duration of antibiotic therapy in community-acquired pneumonia', Pulmonary Pharmacology and Therapeutics, vol. 45, pp. 191-201. https://doi.org/10.1016/j.pupt.2017.06.008
Aliberti, Stefano ; Ramirez, Julio ; Giuliani, Fabio ; Wiemken, Timothy ; Sotgiu, Giovanni ; Tedeschi, Sara ; Carugati, Manuela ; Valenti, Vincenzo ; Marchioni, Marco ; Camera, Marco ; Piro, Roberto ; Del Forno, Manuela ; Milani, Giuseppe ; Faverio, Paola ; Richeldi, Luca ; Deotto, Martina ; Villani, Massimiliano ; Voza, Antonio ; Tobaldini, Eleonora ; Bernardi, Mauro ; Bellone, Andrea ; Bassetti, Matteo ; Blasi, Francesco. / Individualizing duration of antibiotic therapy in community-acquired pneumonia. In: Pulmonary Pharmacology and Therapeutics. 2017 ; Vol. 45. pp. 191-201.
@article{9d0088084fec4c4498806403f51b995b,
title = "Individualizing duration of antibiotic therapy in community-acquired pneumonia",
abstract = "International experts suggest tailoring antibiotic duration in community-acquired pneumonia (CAP) according to patients' characteristics. We aimed to assess the effectiveness of an individualized approach to antibiotic duration based on time in which CAP patients reach clinical stability during hospitalization. In a multicenter, non-inferiority, randomized, controlled trial hospitalized adult patients with CAP reaching clinical stability within 5 days after hospitalization were randomized to a standard vs. individualized antibiotic duration. In the Individualized group, antibiotics were discontinued 48 h after the patient reached clinical stability, with at least five days of total antibiotic treatment. Early failure within 30 days was the primary composite outcome. 135 patients were randomized to the Standard group and 125 to the Individualized group. The trial was interrupted by the safety committee because of an apparent inferiority of the Individualized group over the Standard treatment: 14 (11.2{\%}) patients in the Individualized group experienced early failure vs. 10 (7.4{\%}) patients in the Standard group, p = 0.200, at the intention-to-treat analysis. 30-day mortality rate was four-time higher in the Individualized group than the Standard group. Shortening antibiotic duration according to patients' characteristics still remains an open question.",
author = "Stefano Aliberti and Julio Ramirez and Fabio Giuliani and Timothy Wiemken and Giovanni Sotgiu and Sara Tedeschi and Manuela Carugati and Vincenzo Valenti and Marco Marchioni and Marco Camera and Roberto Piro and {Del Forno}, Manuela and Giuseppe Milani and Paola Faverio and Luca Richeldi and Martina Deotto and Massimiliano Villani and Antonio Voza and Eleonora Tobaldini and Mauro Bernardi and Andrea Bellone and Matteo Bassetti and Francesco Blasi",
year = "2017",
month = "8",
day = "1",
doi = "10.1016/j.pupt.2017.06.008",
language = "English",
volume = "45",
pages = "191--201",
journal = "Pulmonary Pharmacology and Therapeutics",
issn = "1094-5539",
publisher = "Academic Press",

}

TY - JOUR

T1 - Individualizing duration of antibiotic therapy in community-acquired pneumonia

AU - Aliberti, Stefano

AU - Ramirez, Julio

AU - Giuliani, Fabio

AU - Wiemken, Timothy

AU - Sotgiu, Giovanni

AU - Tedeschi, Sara

AU - Carugati, Manuela

AU - Valenti, Vincenzo

AU - Marchioni, Marco

AU - Camera, Marco

AU - Piro, Roberto

AU - Del Forno, Manuela

AU - Milani, Giuseppe

AU - Faverio, Paola

AU - Richeldi, Luca

AU - Deotto, Martina

AU - Villani, Massimiliano

AU - Voza, Antonio

AU - Tobaldini, Eleonora

AU - Bernardi, Mauro

AU - Bellone, Andrea

AU - Bassetti, Matteo

AU - Blasi, Francesco

PY - 2017/8/1

Y1 - 2017/8/1

N2 - International experts suggest tailoring antibiotic duration in community-acquired pneumonia (CAP) according to patients' characteristics. We aimed to assess the effectiveness of an individualized approach to antibiotic duration based on time in which CAP patients reach clinical stability during hospitalization. In a multicenter, non-inferiority, randomized, controlled trial hospitalized adult patients with CAP reaching clinical stability within 5 days after hospitalization were randomized to a standard vs. individualized antibiotic duration. In the Individualized group, antibiotics were discontinued 48 h after the patient reached clinical stability, with at least five days of total antibiotic treatment. Early failure within 30 days was the primary composite outcome. 135 patients were randomized to the Standard group and 125 to the Individualized group. The trial was interrupted by the safety committee because of an apparent inferiority of the Individualized group over the Standard treatment: 14 (11.2%) patients in the Individualized group experienced early failure vs. 10 (7.4%) patients in the Standard group, p = 0.200, at the intention-to-treat analysis. 30-day mortality rate was four-time higher in the Individualized group than the Standard group. Shortening antibiotic duration according to patients' characteristics still remains an open question.

AB - International experts suggest tailoring antibiotic duration in community-acquired pneumonia (CAP) according to patients' characteristics. We aimed to assess the effectiveness of an individualized approach to antibiotic duration based on time in which CAP patients reach clinical stability during hospitalization. In a multicenter, non-inferiority, randomized, controlled trial hospitalized adult patients with CAP reaching clinical stability within 5 days after hospitalization were randomized to a standard vs. individualized antibiotic duration. In the Individualized group, antibiotics were discontinued 48 h after the patient reached clinical stability, with at least five days of total antibiotic treatment. Early failure within 30 days was the primary composite outcome. 135 patients were randomized to the Standard group and 125 to the Individualized group. The trial was interrupted by the safety committee because of an apparent inferiority of the Individualized group over the Standard treatment: 14 (11.2%) patients in the Individualized group experienced early failure vs. 10 (7.4%) patients in the Standard group, p = 0.200, at the intention-to-treat analysis. 30-day mortality rate was four-time higher in the Individualized group than the Standard group. Shortening antibiotic duration according to patients' characteristics still remains an open question.

UR - http://www.scopus.com/inward/record.url?scp=85022174684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85022174684&partnerID=8YFLogxK

U2 - 10.1016/j.pupt.2017.06.008

DO - 10.1016/j.pupt.2017.06.008

M3 - Article

AN - SCOPUS:85022174684

VL - 45

SP - 191

EP - 201

JO - Pulmonary Pharmacology and Therapeutics

JF - Pulmonary Pharmacology and Therapeutics

SN - 1094-5539

ER -